Case reports of acquired thrombotic thrombocytopenic purpura attributed to pembrolizumab

Case reports of acquired thrombotic thrombocytopenic purpura attributed to pembrolizumab

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of oncology pharmacy practice 2022-07, Vol.28 (5), p.1286-1287
Hauptverfasser: Gilbar, Peter J, Dickey, Marcus SR
Format: Artikel
Sprache:eng
Schlagworte:
Antibodies, Monoclonal, Humanized - adverse effects
Case reports
Humans
Pembrolizumab
Purpura, Thrombotic Thrombocytopenic - chemically induced
Purpura, Thrombotic Thrombocytopenic - diagnosis
Thrombocytopenic purpura
Thrombotic thrombocytopenic purpura
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1287
container_issue 5
container_start_page 1286
container_title Journal of oncology pharmacy practice
container_volume 28
creator Gilbar, Peter J
Dickey, Marcus SR
description
doi_str_mv 10.1177/10781552221088025
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2828299809</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_10781552221088025</sage_id><sourcerecordid>2828299809</sourcerecordid><originalsourceid>FETCH-LOGICAL-c335t-c76b78afc0af455ff718ded123767b0433451f99e7e2b81a44ecc67ed51444cd3</originalsourceid><addsrcrecordid>eNp1kE1LAzEQhoMotlZ_gBdZ8Lw1k49N9ijFLyh4UehtSbJZ3dJttkn2UH-9KW31IDIDM8w88w68CF0DngIIcQdYSOCcEAJYSkz4CRoDEyLHJVmcpj7t8x0wQhchLDHGUhB5jkaUU1yUAGO0mKlgM29752PIXJMpsxlab-ssfnrXaRdbc2zNNrrertOgH3xKlakYfauHuMNd1ttOe7dqv4ZO6Ut01qhVsFeHOkHvjw9vs-d8_vr0Mruf54ZSHnMjCi2kagxWDeO8aQTI2tZAqCiExoxSxqEpSyss0RIUY9aYQtiaA2PM1HSCbve6vXebwYZYLd3g1-llRWSKspS4TBTsKeNdCN42Ve_bTvltBbjaeVn98TLd3ByUB93Z-ufiaF4CpnsgqA_7-_Z_xW9UBH1a</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2828299809</pqid></control><display><type>article</type><title>Case reports of acquired thrombotic thrombocytopenic purpura attributed to pembrolizumab</title><source>Access via SAGE</source><source>MEDLINE</source><creator>Gilbar, Peter J ; Dickey, Marcus SR</creator><creatorcontrib>Gilbar, Peter J ; Dickey, Marcus SR</creatorcontrib><identifier>ISSN: 1078-1552</identifier><identifier>EISSN: 1477-092X</identifier><identifier>DOI: 10.1177/10781552221088025</identifier><identifier>PMID: 35306911</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Antibodies, Monoclonal, Humanized - adverse effects ; Case reports ; Humans ; Pembrolizumab ; Purpura, Thrombotic Thrombocytopenic - chemically induced ; Purpura, Thrombotic Thrombocytopenic - diagnosis ; Thrombocytopenic purpura ; Thrombotic thrombocytopenic purpura</subject><ispartof>Journal of oncology pharmacy practice, 2022-07, Vol.28 (5), p.1286-1287</ispartof><rights>The Author(s) 2022</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c335t-c76b78afc0af455ff718ded123767b0433451f99e7e2b81a44ecc67ed51444cd3</citedby><cites>FETCH-LOGICAL-c335t-c76b78afc0af455ff718ded123767b0433451f99e7e2b81a44ecc67ed51444cd3</cites><orcidid>0000-0001-7748-1891</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/10781552221088025$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/10781552221088025$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,21819,27924,27925,43621,43622</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35306911$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gilbar, Peter J</creatorcontrib><creatorcontrib>Dickey, Marcus SR</creatorcontrib><title>Case reports of acquired thrombotic thrombocytopenic purpura attributed to pembrolizumab</title><title>Journal of oncology pharmacy practice</title><addtitle>J Oncol Pharm Pract</addtitle><subject>Antibodies, Monoclonal, Humanized - adverse effects</subject><subject>Case reports</subject><subject>Humans</subject><subject>Pembrolizumab</subject><subject>Purpura, Thrombotic Thrombocytopenic - chemically induced</subject><subject>Purpura, Thrombotic Thrombocytopenic - diagnosis</subject><subject>Thrombocytopenic purpura</subject><subject>Thrombotic thrombocytopenic purpura</subject><issn>1078-1552</issn><issn>1477-092X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kE1LAzEQhoMotlZ_gBdZ8Lw1k49N9ijFLyh4UehtSbJZ3dJttkn2UH-9KW31IDIDM8w88w68CF0DngIIcQdYSOCcEAJYSkz4CRoDEyLHJVmcpj7t8x0wQhchLDHGUhB5jkaUU1yUAGO0mKlgM29752PIXJMpsxlab-ssfnrXaRdbc2zNNrrertOgH3xKlakYfauHuMNd1ttOe7dqv4ZO6Ut01qhVsFeHOkHvjw9vs-d8_vr0Mruf54ZSHnMjCi2kagxWDeO8aQTI2tZAqCiExoxSxqEpSyss0RIUY9aYQtiaA2PM1HSCbve6vXebwYZYLd3g1-llRWSKspS4TBTsKeNdCN42Ve_bTvltBbjaeVn98TLd3ByUB93Z-ufiaF4CpnsgqA_7-_Z_xW9UBH1a</recordid><startdate>202207</startdate><enddate>202207</enddate><creator>Gilbar, Peter J</creator><creator>Dickey, Marcus SR</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><orcidid>https://orcid.org/0000-0001-7748-1891</orcidid></search><sort><creationdate>202207</creationdate><title>Case reports of acquired thrombotic thrombocytopenic purpura attributed to pembrolizumab</title><author>Gilbar, Peter J ; Dickey, Marcus SR</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c335t-c76b78afc0af455ff718ded123767b0433451f99e7e2b81a44ecc67ed51444cd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antibodies, Monoclonal, Humanized - adverse effects</topic><topic>Case reports</topic><topic>Humans</topic><topic>Pembrolizumab</topic><topic>Purpura, Thrombotic Thrombocytopenic - chemically induced</topic><topic>Purpura, Thrombotic Thrombocytopenic - diagnosis</topic><topic>Thrombocytopenic purpura</topic><topic>Thrombotic thrombocytopenic purpura</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gilbar, Peter J</creatorcontrib><creatorcontrib>Dickey, Marcus SR</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><jtitle>Journal of oncology pharmacy practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gilbar, Peter J</au><au>Dickey, Marcus SR</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Case reports of acquired thrombotic thrombocytopenic purpura attributed to pembrolizumab</atitle><jtitle>Journal of oncology pharmacy practice</jtitle><addtitle>J Oncol Pharm Pract</addtitle><date>2022-07</date><risdate>2022</risdate><volume>28</volume><issue>5</issue><spage>1286</spage><epage>1287</epage><pages>1286-1287</pages><issn>1078-1552</issn><eissn>1477-092X</eissn><cop>London, England</cop><pub>SAGE Publications</pub><pmid>35306911</pmid><doi>10.1177/10781552221088025</doi><tpages>2</tpages><orcidid>https://orcid.org/0000-0001-7748-1891</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1078-1552
ispartof Journal of oncology pharmacy practice, 2022-07, Vol.28 (5), p.1286-1287
issn 1078-1552
1477-092X
language eng
recordid cdi_proquest_journals_2828299809
source Access via SAGE; MEDLINE
subjects Antibodies, Monoclonal, Humanized - adverse effects
Case reports
Humans
Pembrolizumab
Purpura, Thrombotic Thrombocytopenic - chemically induced
Purpura, Thrombotic Thrombocytopenic - diagnosis
Thrombocytopenic purpura
Thrombotic thrombocytopenic purpura
title Case reports of acquired thrombotic thrombocytopenic purpura attributed to pembrolizumab
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T10%3A37%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Case%20reports%20of%20acquired%20thrombotic%20thrombocytopenic%20purpura%20attributed%20to%20pembrolizumab&rft.jtitle=Journal%20of%20oncology%20pharmacy%20practice&rft.au=Gilbar,%20Peter%20J&rft.date=2022-07&rft.volume=28&rft.issue=5&rft.spage=1286&rft.epage=1287&rft.pages=1286-1287&rft.issn=1078-1552&rft.eissn=1477-092X&rft_id=info:doi/10.1177/10781552221088025&rft_dat=%3Cproquest_cross%3E2828299809%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2828299809&rft_id=info:pmid/35306911&rft_sage_id=10.1177_10781552221088025&rfr_iscdi=true